Biover­a­tiv climbs on board Bi­cy­cle's pep­tide plat­form in dis­cov­ery deal; Iron­wood CFO jumps ship, joins Ver­tex

⇨ Bio­gen spin­out Biover­a­tiv is col­lab­o­rat­ing with Bi­cy­cle Ther­a­peu­tics on new he­mo­phil­ia and sick­le cell dis­ease pep­tide ther­a­pies. The deal comes with $10 mil­lion up front and $4.2 mil­lion for re­search sup­port. Then there’s $410 mil­lion in mile­stones that add up for a string of po­ten­tial suc­cess­es.

⇨ Tom Graney is jump­ing ship at Iron­wood $IR­WD and mov­ing over to Ver­tex $VRTX as its new CFO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER